{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:24:41Z","timestamp":1778750681267,"version":"3.51.4"},"reference-count":66,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The sodium-glucose cotransporter (SGLT) inhibitors represent a new alternative for treating patients with diabetes mellitus. They act primarily by inhibiting glucose reabsorption in the renal tubule and therefore, decreasing blood glucose levels. While little is yet known about SGLT subtype 1, SGLT2 inhibitors have demonstrated to significantly reduce cardiovascular mortality and heart failure hospitalizations. This cardioprotective benefit seems to be independent of their glucose-lowering properties; however, the underlying mechanism(s) remains still unclear and numerous hypotheses have been postulated to date. Moreover, preclinical research has suggested an important role of SGLT1 receptors on myocardial ischemia. Following acute phase of cardiac injury there is an increased activity of SGLT1 cotransport that ensures adequate energy supply to the cardiac cells. Nonetheless, a long-term upregulation of this receptor may not be that beneficial and whether its inhibition is positive or not should be further addressed. This review aims to present the most cutting-edge insights into SGLT receptors.<\/jats:p>","DOI":"10.3390\/ijms20133289","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T11:13:18Z","timestamp":1562238798000},"page":"3289","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance"],"prefix":"10.3390","volume":"20","author":[{"given":"\u00c1lvaro","family":"Garc\u00eda-Ropero","sequence":"first","affiliation":[{"name":"Atherothrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"Cardiology Department, Imperial College London, The Royal Brompton and Harefield Hospital, London 6W3 6NP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariana","family":"Vargas-Delgado","sequence":"additional","affiliation":[{"name":"Atherothrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"},{"name":"Instituto Ecuatoriano del Coraz\u00f3n IECOR, Guayaquil 090513, Ecuador"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1408-8958","authenticated-orcid":false,"given":"Carlos","family":"Santos-Gallego","sequence":"additional","affiliation":[{"name":"Atherothrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-8771","authenticated-orcid":false,"given":"Juan","family":"Badimon","sequence":"additional","affiliation":[{"name":"Atherothrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,7,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0735-1097(02)02160-5","article-title":"Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with31P-SLOOP magnetic resonance spectroscopy","volume":"40","author":"Beer","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/CIRCRESAHA.112.268128","article-title":"Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy","volume":"111","author":"Kolwicz","year":"2012","journal-title":"Circ. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1073\/pnas.97.4.1784","article-title":"Lipotoxic heart disease in obese rats: Implications for human obesity","volume":"97","author":"Zhou","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: A systematic analysis for the Global Burden of Disease Study 2013","volume":"385","author":"Abubakar","year":"2015","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canvas","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10557-018-6786-x","article-title":"Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?","volume":"32","author":"Flores","year":"2018","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","article-title":"Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target","volume":"243","author":"Cantini","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-018-06850-0","article-title":"Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the \u201cCardiac Benefits\u201d of Empagliflozin Independent of its Hypoglycemic Activity?","volume":"33","author":"Mancini","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1016\/j.ijcard.2013.07.150","article-title":"An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy","volume":"168","author":"Palomer","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jacbts.2016.11.009","article-title":"Metabolic Origins of Heart Failure","volume":"2","author":"Wende","year":"2017","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/CIRCRESAHA.113.300376","article-title":"Cardiac Metabolism in Heart Failure","volume":"113","author":"Doenst","year":"2013","journal-title":"Circ. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.pharmthera.2017.08.001","article-title":"Cardiac metabolism\u2014A promising therapeutic target for heart failure","volume":"182","author":"Noordali","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17425255.2019.1588886","article-title":"Metabolism of the failing heart and the impact of SGLT2 inhibitors","volume":"15","author":"Zafar","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1093\/eurheartj\/ehy596","article-title":"Heart failure and diabetes: Metabolic alterations and therapeutic interventions: A state-of-the-art review from the Translational Research Committee of the Heart Failure Association\u2013European Society of Cardiology","volume":"39","author":"Maack","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Nikolajevi\u0107 Star\u010devi\u0107, J., Jani\u0107, M., and \u0160abovi\u010d, M. (2019). Molecular Mechanisms Responsible for Diastolic Dysfunction in Diabetes Mellitus Patients. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051197"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/01.CIR.81.4.1161","article-title":"Ventricular Remodeling After Myocardial Infarction","volume":"81","author":"Pfeffer","year":"1990","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10741-010-9181-7","article-title":"Left ventricular remodeling in the post-infarction heart: A review of cellular, molecular mechanisms, and therapeutic modalities","volume":"16","author":"Gajarsa","year":"2011","journal-title":"Heart Fail. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/cvr\/cvn333","article-title":"Myocardial repair\/remodelling following infarction: Roles of local factors","volume":"81","author":"Sun","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.115.012427","article-title":"Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia\/Reperfusion","volume":"133","author":"Vahl","year":"2016","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.yjmcc.2010.12.021","article-title":"Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction","volume":"50","author":"Vilahur","year":"2011","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1113\/jphysiol.2006.109389","article-title":"AMPK alterations in cardiac physiology and pathology: Enemy or ally?","volume":"574","author":"Dyck","year":"2006","journal-title":"J. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1161\/CIRCULATIONAHA.105.550806","article-title":"Increased \u03b12 Subunit\u2013Associated AMPK Activity and PRKAG2 Cardiomyopathy","volume":"112","author":"Goodyear","year":"2005","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cvr\/cvp190","article-title":"SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states","volume":"84","author":"Banerjee","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1517\/14728222.2016.1168808","article-title":"Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus","volume":"20","author":"Song","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbrc.2003.12.090","article-title":"Na+-D-glucose cotransporter in muscle capillaries increases glucose permeability","volume":"314","author":"Elfeber","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MNH.0000000000000152","article-title":"Sodium-glucose cotransport","volume":"24","author":"Poulsen","year":"2015","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1071-3581(00)70016-X","article-title":"Cellular and molecular regulation of cardiac glucose transport","volume":"7","author":"Young","year":"2000","journal-title":"J. Nucl. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijcard.2016.12.083","article-title":"Glucose transporters in healthy heart and in cardiac disease","volume":"230","author":"Szablewski","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.yjmcc.2010.06.003","article-title":"SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy","volume":"49","author":"Banerjee","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e000899","DOI":"10.1161\/JAHA.114.000899","article-title":"Transgenic Knockdown of Cardiac Sodium\/Glucose Cotransporter 1 (SGLT1) Attenuates PRKAG2 Cardiomyopathy, Whereas Transgenic Overexpression of Cardiac SGLT1 Causes Pathologic Hypertrophy and Dysfunction in Mice","volume":"3","author":"Ramratnam","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_35","unstructured":"Jakubiak, M., Agrawal, V., D\u2019Auria, S., Li, Z., Ramratnam, M., Sincoular, A., Sharma, R.K., Music, M.L., Gifford, L., and Huang, X.N. (2019). Cardiac Sodium-Glucose Co-Transporter 1 (SGLT1) is a Novel Mediator of Ischemia\/Reperfusion Injury. Cardiovasc. Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Garcia-Ropero, A., Santos-Gallego, C.G., and Badimon, J.J. (2019). SGLT receptors and myocardial ischaemia-reperfusion injury: Inhibition of SGLT-1, SGLT-2, or both?. Cardiovasc. Res.","DOI":"10.1093\/cvr\/cvz077"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12933-018-0741-9","article-title":"Dual inhibition of sodium\u2013glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction","volume":"17","author":"Connelly","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kashiwagi, Y., Nagoshi, T., Yoshino, T., Tanaka, T.D., Ito, K., Harada, T., Takahashi, H., Ikegami, M., Anzawa, R., and Yoshimura, M. (2015). Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0130605"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e001007","DOI":"10.1136\/bmjopen-2012-001007","article-title":"Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes","volume":"2","author":"Clar","year":"2012","journal-title":"BMJ Open"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/17425255.2018.1551877","article-title":"The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: The latest developments","volume":"14","author":"Badimon","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fendo.2019.00314","article-title":"Editorial: Cardiovascular Disease and Diabetes","volume":"10","author":"Santulli","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-018-0719-7","article-title":"Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure","volume":"17","author":"Tanaka","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1161\/CIRCULATIONAHA.118.037599","article-title":"Primary Prevention of Heart Failure in Patients with Type 2 Diabetes Mellitus","volume":"139","author":"Greene","year":"2019","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin Ameliorates Adverse LV Remodeling in a Non-Diabetic Model of Heart Failure Mediated via a Switch in Myocardial Metabolism That Enhances Energetics","volume":"73","author":"Picatoste","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Yurista, S.R., Sillj\u00e9, H.H., Oberdorf-Maass, S.U., Schouten, E., Pavez Giani, M.G., Hillebrands, J., van Goor, H., van Veldhuisen, D.J., de Boer, R.A., and Westenbrink, B.D. (2019). Sodium\u2013glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur. J. Heart Fail.","DOI":"10.1002\/ejhf.1473"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00395-019-0733-2","article-title":"Inhibition of sodium\u2013glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization","volume":"114","author":"Baker","year":"2019","journal-title":"Basic Res. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lfs.2019.05.051","article-title":"Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy","volume":"230","author":"Takasu","year":"2019","journal-title":"Life Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV Protection in the EMPA-REG OUTCOME Trial: A \u201cThrifty Substrate\u201d Hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"A674","DOI":"10.1016\/S0735-1097(18)31215-4","article-title":"Empagliflozin Induces a Myocardial Metabolic Shift from Glucose Consumption to Ketone Metabolism That Mitigates Adverse Cardiac Remodeling and Improves Myocardial Contractility","volume":"71","author":"Ibanez","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"A17367","DOI":"10.1161\/circ.138.suppl_1.17367","article-title":"Abstract 17367: Infusion of the Ketone Body \u03b2-Hydroxybutyrate Improves Left Ventricular Systolic Function in an Animal Model of Heart Failure with Reduced Ejection Fraction","volume":"138","author":"SantosGallego","year":"2018","journal-title":"Circulation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.yjmcc.2013.09.013","article-title":"Loss of NHE1 activity leads to reduced oxidative stress in heart and mitigates high-fat diet-induced myocardial stress","volume":"65","author":"Prasad","year":"2013","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: Inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12933-018-0790-0","article-title":"A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats","volume":"17","author":"Durak","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1016\/j.cjca.2017.07.330","article-title":"Direct effect of empagliflozin on extracellular matrix remodeling in human cardiac fibroblasts: Novel translational clues to EMPA-REG OUTCOME","volume":"33","author":"Kang","year":"2017","journal-title":"Can. J. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1089\/dia.2018.0081","article-title":"Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care","volume":"20","author":"Danne","year":"2018","journal-title":"Diabetes Technol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"ACCORD Study Group, Miller, M., Genuth, S., Ismail-Beigi, F., Buse, J., Goff, J., Probstfield, J., Cushman, W., Ginsberg, H., and Bigger, J. (2011). Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J. Med., 364, 818\u2013828.","DOI":"10.1056\/NEJMoa1006524"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/ehf2.12345","article-title":"Empagliflozin, calcium, and SGLT1\/2 receptor affinity: Another piece of the puzzle","volume":"5","author":"Anker","year":"2018","journal-title":"ESC Heart Fail."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Heart Fail."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Lee, T.-I., Chen, Y.-C., Lin, Y.-K., Chung, C.-C., Lu, Y.-Y., Kao, Y.-H., and Chen, Y.-J. (2019). Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20071680"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/CIRCULATIONAHA.117.030117","article-title":"Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes","volume":"137","author":"Bethel","year":"2018","journal-title":"Circulation"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: Results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/13\/3289\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:02:32Z","timestamp":1760187752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/13\/3289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,4]]},"references-count":66,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2019,7]]}},"alternative-id":["ijms20133289"],"URL":"https:\/\/doi.org\/10.3390\/ijms20133289","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,4]]}}}